Atossa Therapeutics, Inc. - Common Stock (ATOS)
Frequently Asked Questions About Atossa Therapeutics, Inc. - Common Stock (ATOS)
Has Atossa Therapeutics developed any drugs?
Yes, Atossa Therapeutics has developed several drug candidates, including the topical drug candidate Endoxifen, which is being investigated for its potential therapeutic effects in treating breast cancer.
How can I invest in Atossa Therapeutics?
You can invest in Atossa Therapeutics by purchasing shares through a brokerage account, as the company's stock is publicly traded on the Nasdaq under the ticker symbol ATOS.
How does Atossa Therapeutics approach innovation?
Atossa Therapeutics approaches innovation through a combination of cutting-edge research, collaboration with leading scientists, and a commitment to developing therapies that address current gaps in breast cancer treatment.
How is Atossa's business model structured?
Atossa's business model is structured around the development and commercialization of innovative therapeutics for breast cancer, supported by collaborations, licensing agreements, and partnerships with academic and research institutions.
What are the key challenges faced by Atossa?
Some key challenges faced by Atossa include navigating the complex regulatory landscape for drug approvals, securing funding for clinical trials, and competing in the rapidly evolving biotechnology sector.
What are the recent developments in Atossa's pipeline?
Recent developments in Atossa's pipeline include progress in clinical trials for its drug candidates and partnerships aimed at enhancing research and potential market reach for its therapeutic solutions.
What collaborations does Atossa have?
Atossa has established collaborations with various academic institutions, clinical research organizations, and industry partners to enhance its research capabilities and accelerate the development of its drug candidates.
What does Atossa Therapeutics, Inc. do?
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutic and diagnostic solutions for breast cancer and other breast diseases, seeking to address the unmet medical needs of patients through its research and product pipeline.
What financial updates does Atossa provide to investors?
Atossa provides regular financial updates to investors, including quarterly earnings reports, clinical trial progress disclosures, and strategic plans for the future of the company, ensuring transparency and keeping stakeholders informed.
What initiatives has Atossa undertaken for patient engagement?
Atossa has undertaken several initiatives for patient engagement, including educational campaigns, partnerships with patient advocacy groups, and forums to discuss treatment options for breast cancer and related conditions.
What is Atossa's commitment to sustainability?
Atossa Therapeutics is committed to sustainability by implementing responsible business practices, focusing on ethical research methodologies, and considering environmental impacts in its operations.
What is Endoxifen?
Endoxifen is a proprietary oral drug candidate being developed by Atossa for the treatment of breast cancer. It is an active metabolite of Tamoxifen and is designed to improve therapeutic outcomes and reduce side effects.
What is the focus area of Atossa's research?
Atossa's research focuses primarily on breast cancer and related conditions, including the development of novel therapies to address issues such as tumor growth, prevention, and post-surgical management.
What is the market focus of Atossa's drug candidates?
The market focus of Atossa's drug candidates is primarily on breast cancer, aiming to provide innovative solutions for treatment, prevention, and increasing the quality of life for patients.
What is the significance of Atossa's clinical trials?
Atossa's clinical trials are significant because they are crucial in evaluating the safety and efficacy of its drug candidates, paving the way for potential approvals by regulatory agencies such as the FDA.
What is the stock symbol for Atossa Therapeutics?
Atossa Therapeutics, Inc. is publicly traded on the Nasdaq stock exchange under the symbol 'ATOS', allowing investors to trade shares of the company.
When was Atossa Therapeutics, Inc. founded?
Atossa Therapeutics, Inc. was founded in 2008, and has since developed a portfolio of proprietary therapies for breast cancer and other breast diseases.
Where is Atossa Therapeutics, Inc. headquartered?
Atossa Therapeutics, Inc. is headquartered in Seattle, Washington, which positions the company in a vibrant biotech hub with access to leading research institutions and healthcare networks.
Who is the CEO of Atossa Therapeutics?
As of the latest information available, the CEO of Atossa Therapeutics is Dr. Steven C. Quay, who brings extensive experience in biotech and pharmaceutical sectors to the company's leadership.
What is the current price of Atossa Therapeutics, Inc. - Common Stock?
The current price of Atossa Therapeutics, Inc. - Common Stock is 2.130
When was Atossa Therapeutics, Inc. - Common Stock last traded?
The last trade of Atossa Therapeutics, Inc. - Common Stock was at 4:00 pm EST on November 9th, 2026
What is the market capitalization of Atossa Therapeutics, Inc. - Common Stock?
The market capitalization of Atossa Therapeutics, Inc. - Common Stock is 267.92M
How many shares of Atossa Therapeutics, Inc. - Common Stock are outstanding?
Atossa Therapeutics, Inc. - Common Stock has 125.79M shares outstanding.